Get the Stockscreener App
0.1963
5.17%
-0.0107
After Hours:
.19
-0.0063
-3.21%
Ernexa Therapeutics Inc stock is traded at $0.1963, with a volume of 137.13K.
It is down -5.17% in the last 24 hours and up +6.17% over the past month.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
See More
Previous Close:
$0.207
Open:
$0.203
24h Volume:
137.13K
Relative Volume:
0.46
Market Cap:
$12.74M
Revenue:
$598.00K
Net Income/Loss:
$-44.93M
P/E Ratio:
-0.0236
EPS:
-8.31
Net Cash Flow:
$-17.32M
1W Performance:
-4.20%
1M Performance:
+6.17%
6M Performance:
-81.12%
1Y Performance:
-88.97%
1-Day Range:
$0.1921
$0.217
1-Week Range:
$0.19
$0.23
52-Week Range:
$0.1506
$2.625
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Name
Ernexa Therapeutics Inc
Sector
Industry
Phone
(212) 582-1199
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
0.1963 | 12.74M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.86 | 126.60B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
590.00 | 64.75B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
639.90 | 36.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.13 | 31.40B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
102.43 | 28.98B | 2.98B | -717.57M | -264.74M | -2.9987 |
Ernexa Therapeutics Inc Stock (ERNA) Latest News
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025 - GlobeNewswire
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025 - The Manila Times
Ernexa Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ERNA - Benzinga
Ernexa Therapeutics Inc Files Prospectus For Resale Of 10.4 Million Shares Of Common Stock By Selling Stockholder- SEC Filing - marketscreener.com
Eterna therapeutics sees $394,174 stock acquisition by Charles Cherington - Investing.com Australia
ERNA stock touches 52-week low at $0.16 amid sharp annual decline - Investing.com India
Ernexa Therapeutics Closes New Funding Round - GlobeNewswire
Biotech Breakthrough: Ernexa Secures $7.25M to Advance Revolutionary Cancer Treatment - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics By Investing.com - Investing.com Australia
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics - Investing.com
Eterna Therapeutics Changes Name to Ernexa Therapeutics to - GlobeNewswire
Major Pivot: Eterna Becomes Ernexa, Unveils New Cancer and Autoimmune Disease Strategy - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - MarketBeat
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - MarketBeat
Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) Declares $0.09 Monthly Dividend - MarketBeat
Eterna Therapeutics sets annual meeting date, opens nominations - MSN
Better AI Stock: SoundHound AI vs. Broadcom - The Globe and Mail
Eterna Therapeutics Hosts Successful Inaugural Meeting with - GlobeNewswire
Can Eterna's Expert-Backed Cell Therapy Breakthrough Revolutionize Ovarian Cancer Treatment? - StockTitan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World
Eterna Therapeutics (NASDAQ:ERNA) & Galecto (NASDAQ:GLTO) Head to Head Comparison - Defense World
Eterna Therapeutics Inc (ERNA)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - Defense World
Ratio Examination: Eterna Therapeutics Inc (ERNA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
ERNA’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Eterna Therapeutics Inc (ERNA) is a good investment, but the stock may be undervalued - US Post News
Contrasting Eterna Therapeutics (NASDAQ:ERNA) and Anixa Biosciences (NASDAQ:ANIX) - Defense World
Market Insight: Eterna Therapeutics Inc (ERNA)’s Notable Drop, Closing at 0.36 - The Dwinnex
Eterna Therapeutics expands scientific board with oncology experts - MSN
Eterna Therapeutics’ Shares Surge After Promising Preclinical Results for ERNA-101 Cell Therapy - HPBL
Ernexa Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
1.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):